Here is a nice, concise primer article from The Scientist talking about advances that are being pursued with monoclonal antibodies. The article covers new approaches for engineering and selecting antibodies, multi-specific antibodies, antibody-drug conjugates, and Fc modifications to control immume modulation.
It is a good overview to the area and reminds one of the advances still being pursued in the field -- even though mAbs have been around since the 70's. These are technologies that will be incorporated into new drugs in the next decade and will be among the next generation of drug approvals.
Posted by Bruce Lehr Sep 18th 2013.